Pharming Group N.V.(PHAR)Earnings, Financials & Key Ratios
PHAR•NASDAQ
$14.46
361.5× P/E·Price updated Jul 7, 2026
AboutPharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.Show more
- Revenue$377M+26.9%
- EBITDA$31M+311.0%
- Net Income$3M+124.1%
- EPS (Diluted)0.04+123.5%
- Gross Margin87.9%-0.2%
- EBITDA Margin8.12%+223.8%
- Operating Margin5.13%+277.0%
- Net Margin0.76%+119.0%
- ROE1.15%+121.3%
PHAR Price & Volume
Pharming Group N.V. (PHAR) stock price & volume — 10-year historical chart
Loading chart...
Transgenic Platform Efficiency Faces Commercial Scaling Hurdles
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Commercial launch execution uncertainty
Key Thesis Takeaways
- Pharming Group leverages a proprietary transgenic production platform to maintain robust gross margins near 90%, yet the company struggles to translate this technical advantage into consistent bottom-line profitability.
- While the balance sheet shows improved leverage with a debt-to-equity ratio of 0.43, investors should monitor the volatility in quarterly revenue, which saw a 1148.2% surge in 2025Q4 followed by an 8.1% contraction in 2026Q1.
- Future performance remains contingent on the company's ability to scale commercial operations for its orphan drug portfolio while managing the risks associated with a growing $131.0M goodwill balance.
Verdict Logic
while the company maintains a robust 90.8% gross margin, the erratic revenue trajectory and the $131.0M goodwill position suggest that investors should wait for more consistent operating cash flow generation before committing capital.
PHAR Growth Metrics
Pharming Group N.V. (PHAR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years41.36%
5 Years12.19%
3 Years22.41%
TTM33196.33%
Profit CAGR
10 Years-
5 Years-40.31%
3 Years-40.65%
TTM37757.4%
EPS CAGR
10 Years-
5 Years-38.91%
3 Years-37%
TTM186.55%
Return on Capital
10 Years13.11%
5 Years2.2%
3 Years0.53%
Last Year5.45%
PHAR Recent Earnings
Pharming Group N.V. (PHAR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.07-240.0%
$0.05
Rev
$72M-21.3%
$92M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.07-53.3%
$0.15
Rev
$107M-4.7%
$112M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.10+100.0%
$0.05
Rev
$97M-0.9%
$98M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.06+160.0%
$0.10
Rev
$111M+37.9%
$80M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.07vs $0.05-240.0% | $72Mvs $92M-21.3% |
| Q2 2026 | Mar 12, 2026 | $0.07vs $0.15-53.3% | $107Mvs $112M-4.7% |
| Q4 2025 | Nov 6, 2025 | $0.10vs $0.05+100.0% | $97Mvs $98M-0.9% |
| Q3 2025 | Jul 31, 2025 | $0.06vs $0.10+160.0% | $111Mvs $80M+37.9% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Pharming Group N.V. (PHAR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.46 | $1.01B | 361.50 | 26.91% | 0.76% | 1.15% | — | |
| $319.43 | $6.4B | 52.11 | 60.4% | 55.95% | 16.19% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $368.60 | $10.87B | 53.89 | 33.94% | 53.92% | 19.25% | — |
Compare PHAR vs Peers
Pharming Group N.V. (PHAR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PHAR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PHAR Frequently Asked Questions
Pharming Group N.V. (PHAR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Pharming Group N.V.'s revenue?
Pharming Group N.V. (PHAR) reported $106.76B in revenue for fiscal year 2025. This represents a 22257029% increase from $0.5M in 2005.
How fast is Pharming Group N.V. growing?
Pharming Group N.V. (PHAR) grew revenue by 26.9% over the past year. This is strong growth.
Is PHAR profitable?
Yes, Pharming Group N.V. (PHAR) is profitable, generating $5.31B in net income for fiscal year 2025 (0.8% net margin).
Dividend & Returns
What is PHAR's return on equity?
Pharming Group N.V. (PHAR) has a return on equity (ROE) of 1.1%. This is below average, suggesting room for improvement.
What is Pharming Group N.V.'s free cash flow?
Pharming Group N.V. (PHAR) generated $50.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.